. The neuroprotective and neurotrophic agent T-817MA for Alzheimer’s disease: Randomized, double-blind, placebo-controlled proof-of-concept trial outcomes. Alzheimer's & Dementia, July 2013

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Edonerpic